The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


Published online June 19, 2009
The Journal of Immunology, 2009, 183, 841 -848
Copyright © 2009 by The American Association of Immunologists, Inc.
doi:10.4049/jimmunol.0802046

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jimmunol.0802046v1
183/2/841    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Luther, C.
Right arrow Articles by Tolosa, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luther, C.
Right arrow Articles by Tolosa, E.

Prednisolone Treatment Induces Tolerogenic Dendritic Cells and a Regulatory Milieu in Myasthenia Gravis Patients1

Claudia Luther2,3,*, Eleni Adamopoulou4,{dagger}, Christina Stoeckle4,*, Verena Brucklacher-Waldert5, Daniela Rosenkranz*, Lars Stoltze*, Sigrid Lauer*, Simone Poeschel*, Arthur Melms* and Eva Tolosa3,5,*

* Department of General Neurology and Neurodegenerative Disorders, Hertie Institute for Clinical Brain Research, Tübingen University Hospital, Germany; and {dagger} Medical Clinic and Policlinic II, Julius-Maximilian University of Würzburg, Germany

FOXP3-expressing naturally occurring CD4+CD25high T regulatory cells (Treg) are relevant in the control of autoimmunity, and a defect in this cell population has been observed in several human autoimmune diseases. We hypothesized that altered functions of peripheral Treg cells might play a role in the immunopathogenesis of myasthenia gravis, a T cell-dependent autoimmune disease characterized by the presence of pathogenic autoantibodies specific for the nicotinic acetylcholine receptor. We report in this study a significant decrease in the in vitro suppressive function of peripheral Treg cells isolated from myasthenia patients in comparison to those from healthy donors. Interestingly, Treg cells from prednisolone-treated myasthenia gravis patients showed an improved suppressive function compared with untreated patients, suggesting that prednisolone may play a role in the control of the peripheral regulatory network. Indeed, prednisolone treatment prevents LPS-induced maturation of monocyte-derived dendritic cells by hampering the up-regulation of costimulatory molecules and by limiting secretion of IL-12 and IL-23, and enhancing IL-10. In addition, CD4+ T cells cultured in the presence of such tolerogenic dendritic cells are hyporesponsive and can suppress autologous CD4+ T cell proliferation. The results shown in this study indicate that prednisolone treatment promotes an environment that favors immune regulation rather than inflammation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the German Research Council (SFB 685 and GK 794), the Fortüne Program of the University of Tübingen and the Myasthenia Gravis Foundation.

2 Current address: Terry Fox Laboratory, British Columbia Cancer Research Centre, Vancouver, Canada.

3 Address correspondence and reprint requests to Drs. Claudia Luther and Eva Tolosa, Terry Fox Laboratory, BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, Canada. E-mail addresses: cluther{at}bccrc.ca and eva.tolosa{at}zmnh.uni-hamburg.de

4 E.A. and C.S. contributed equally to this study.

5 Current address: Institute for Neuroimmunology and Clinical Multiple Sclerosis Research, University Clinic Eppendorf, Hamburg, Germany.

6 Abbreviations used in this paper: Treg, regulatory T cell; iTreg, induced Treg; nTreg, naturally occurring Treg; Tr1, type 1 Treg; MG, myasthenia gravis; AchR, acetylcholine receptor; pred, prednisolone; DC, dendritic cell; DCpred,LPS, prednisolone-treated, LPS-stimulated DC; DCimm, immature DC; DCmat, mature DC; HD, healthy donor; t-MG, treated MG patient; ut-MG, untreated MG patient; Aza, azathioprine; Tresp, responder T cell; MFI, median fluorescence intensity; mo-DC, monocyte-derived DC; FOXP3, forkhead box transcription factor 3.

7 The online version of this article contains supplemental material.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.